DexCom Inc. (DXCM)
DexCom Statistics
Share Statistics
DexCom has 390.77M shares outstanding. The number of shares has increased by -1.74% in one year.
| Shares Outstanding | 390.77M |
| Shares Change (YoY) | -1.74% |
| Shares Change (QoQ) | 0.05% |
| Owned by Institutions (%) | 90.27% |
| Shares Floating | 385.26M |
| Failed to Deliver (FTD) Shares | 33 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 8.81M, so 2.26% of the outstanding shares have been sold short.
| Short Interest | 8.81M |
| Short % of Shares Out | 2.26% |
| Short % of Float | 2.28% |
| Short Ratio (days to cover) | 2.53 |
Valuation Ratios
The PE ratio is 54.61 and the forward PE ratio is 43.93. DexCom's PEG ratio is -39.32.
| PE Ratio | 54.61 |
| Forward PE | 43.93 |
| PS Ratio | 7.8 |
| Forward PS | 3.4 |
| PB Ratio | 14.97 |
| P/FCF Ratio | 49.89 |
| PEG Ratio | -39.32 |
Enterprise Valuation
DexCom has an Enterprise Value (EV) of 33.39B.
| EV / Sales | 8.28 |
| EV / EBITDA | 39.72 |
| EV / EBIT | 33.74 |
| EV / FCF | 52.94 |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of 1.2.
| Current Ratio | 1.47 |
| Quick Ratio | 1.28 |
| Debt / Equity | 1.2 |
| Debt / EBITDA | 3.01 |
| Debt / FCF | 4.01 |
| Interest Coverage | 31.58 |
Financial Efficiency
Return on Equity is 27.4% and Return on Invested Capital is 10.2%.
| Return on Equity | 27.4% |
| Return on Assets | 8.89% |
| Return on Invested Capital | 10.2% |
| Revenue Per Employee | $395.39K |
| Profits Per Employee | $56.49K |
| Employee Count | 10,200 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 2.89 |
Taxes
| Income Tax | 132.8M |
| Effective Tax Rate | 18.73% |
Stock Price Statistics
The stock price has increased by -50.73% in the last 52 weeks. The beta is 1.29, so DexCom's price volatility has been higher than the market average.
| Beta | 1.29 |
| 52-Week Price Change | -50.73% |
| 50-Day Moving Average | 81.2 |
| 200-Day Moving Average | 80.85 |
| Relative Strength Index (RSI) | 34.33 |
| Average Volume (20 Days) | 3.95M |
Income Statement
In the last 12 months, DexCom had revenue of 4.03B and earned 576.2M in profits. Earnings per share was 1.42.
| Revenue | 4.03B |
| Gross Profit | 2.47B |
| Operating Income | 600M |
| Net Income | 576.2M |
| EBITDA | 840.7M |
| EBIT | 627.5M |
| Earnings Per Share (EPS) | 1.42 |
Balance Sheet
The company has 606.1M in cash and 2.53B in debt, giving a net cash position of -1.92B.
| Cash & Cash Equivalents | 606.1M |
| Total Debt | 2.53B |
| Net Cash | -1.92B |
| Retained Earnings | 1.6B |
| Total Assets | 6.48B |
| Working Capital | 1.37B |
Cash Flow
In the last 12 months, operating cash flow was 989.5M and capital expenditures -358.8M, giving a free cash flow of 630.7M.
| Operating Cash Flow | 989.5M |
| Capital Expenditures | -358.8M |
| Free Cash Flow | 630.7M |
| FCF Per Share | 1.56 |
Margins
Gross margin is 61.14%, with operating and profit margins of 14.88% and 14.29%.
| Gross Margin | 61.14% |
| Operating Margin | 14.88% |
| Pretax Margin | 17.58% |
| Profit Margin | 14.29% |
| EBITDA Margin | 20.85% |
| EBIT Margin | 14.88% |
| FCF Margin | 15.64% |
Dividends & Yields
DXCM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 1.83% |
| FCF Yield | 2% |
Analyst Forecast
The average price target for DXCM is $100, which is 46.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $100 |
| Price Target Difference | 46.5% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
Stock Splits
The last stock split was on Jun 13, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Jun 13, 2022 |
| Split Type | forward |
| Split Ratio | 4:1 |
Scores
| Altman Z-Score | 5.18 |
| Piotroski F-Score | 6 |